DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2019 của Acceleron Pharma Inc.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. It develops sotatercept and ACE-536 that are in Phase II clinical trials to treat anemia and associated complications in patients with ß-thalassemia and myelodysplastic syndromes, and red blood cell disorders; and dalantercept, which is in Phase II clinical trials to inhibit blood vessel formation in tumors through the vascular endothelial growth factor pathway inhibitors.

TÊN CÔNG TY / COMPANY
Acceleron Pharma Inc.

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NASDAQ (US)

MÃ CHỨNG KHOÁN / TICKER
XLRN

KỲ BÁO CÁO
2019

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare